Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Multiple abnormalities

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    412 result(s) found for: Multiple abnormalities. Displaying page 1 of 21.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2021-002810-15 Sponsor Protocol Number: CHUB-Neuro-ENMG-MS Start Date*: 2021-06-25
    Sponsor Name:CHU Brugmann
    Full Title: Peripheral neuropathy as potential side effect in patients with multiple sclerosis treated with teriflunomide.
    Medical condition: Multiple sclerosis, treated with teriflunomide
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2022-000259-35 Sponsor Protocol Number: 2020_03 Start Date*: 2022-04-29
    Sponsor Name:Centre Hospitalier Universitaire de Lille
    Full Title: Assessment of the interest of a peri-operative antibiotic strategy applied to patients with asymptomatic bacteriuria undergoing intra-vesical botulinum toxin A injections
    Medical condition: Overactive bladder (OAB) and/or detrusor overactivity (DO) in multiple sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000653-32 Sponsor Protocol Number: CFTY720DDE17 Start Date*: 2012-06-27
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A 1-week, open-label, multi-center study to explore conduction abnormalities during first dose administration of fingolimod in patients with relapsing-remitting multiple sclerosis (START)
    Medical condition: Conduction abnormalities in patients with relapsing-remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-004264-39 Sponsor Protocol Number: 26866138-MMY-2060 Start Date*: 2009-01-30
    Sponsor Name:Janssen-Cilag EMEA Medical Affairs
    Full Title: A Phase 2, Multicentre, Randomised, Open-Label, Parallel Group Study to Evaluate the Effect of VELCADE® on Myeloma related Bone Disease
    Medical condition: Myeloma related bone disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DK (Completed) AT (Completed) GB (Completed) SE (Completed) DE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2009-014644-11 Sponsor Protocol Number: MSA-RAS-202 Start Date*: 2009-12-08
    Sponsor Name:Teva Pharmaceutical Industries Ltd
    Full Title: A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy o...
    Medical condition: Multiple System Atrophy of the Parkinsonian Subtype
    Disease: Version SOC Term Classification Code Term Level
    12.0 10064060 Multiple system atrophy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) ES (Completed) HU (Completed) AT (Completed) NL (Completed) IT (Completed) PT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-000253-92 Sponsor Protocol Number: EHP-101-MS02 Start Date*: 2022-10-14
    Sponsor Name:Emerald Health Pharmaceuticals Inc.
    Full Title: A Phase IIa, Open-label, Multicentre Dose-Finding Trial in Patients with Relapsing Forms of Multiple Sclerosis (RMS) to Evaluate the Safety, Tolerability and Preliminary Efficacy of EHP-101
    Medical condition: Relapsing Forms of Multiple Sclerosis (RMS)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029205 - Nervous system disorders 10080700 Relapsing multiple sclerosis PT
    21.1 10029205 - Nervous system disorders 10063400 Secondary progressive multiple sclerosis PT
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004145-16 Sponsor Protocol Number: Z7219K01 Start Date*: 2019-07-24
    Sponsor Name:Zambon SpA
    Full Title: A 12-weeks, multicentre, randomized, double-blind, placebo-controlled, exploratory, pilot study to evaluate the safety and efficacy of safinamide 200 mg once daily, as add-on therapy, in patients w...
    Medical condition: Parkinsonian variant of Multiple System Atrophy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10064060 Multiple system atrophy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-001030-17 Sponsor Protocol Number: CA209-039 Start Date*: 2018-12-20
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Multiple Phase 1/2 Cohorts of Nivolumab Monotherapy or Nivolumab Combination Regimens Across Relapsed/Refractory Hematologic Malignancies
    Medical condition: Multiple myeloma (current protocol)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) BE (Completed) PL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022515-20 Sponsor Protocol Number: A5481004 Start Date*: 2011-02-22
    Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY 10017, USA
    Full Title: PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY AND EFFICACY OF PD 0332991 IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH REFRACTORY MULTIPLE MYELOMA
    Medical condition: Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-001161-14 Sponsor Protocol Number: CAMMS 323 Start Date*: 2007-08-24
    Sponsor Name:Genzyme Corporation
    Full Title: A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in treatment Naïve Patients with Rela...
    Medical condition: Relapsing Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) CZ (Completed) SE (Completed) FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-000750-66 Sponsor Protocol Number: 12-02 Start Date*: 2013-07-02
    Sponsor Name:ICORG-the All Ireland Co-operative Oncology Research Group
    Full Title: Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma
    Medical condition: Asymptomatic High-Risk Smoldering Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000320-33 Sponsor Protocol Number: HOVON_123_MM Start Date*: 2013-11-14
    Sponsor Name:HOVON Foundation
    Full Title: Feasibility and Efficacy of dose adjusted Melphalan – Prednisone – Bortezomib (MPV) in elderly patients ≥ 75 years of age with newly diagnosed Multiple Myeloma; a nonrandomised phase II study
    Medical condition: Newly diagnosed symptomatic Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2007-004122-24 Sponsor Protocol Number: CFTY720D2301E1 Start Date*: 2008-01-23
    Sponsor Name:Novartis Pharma AG
    Full Title: An extension of the 24-month, double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing efficacy and safety of FTY720 1.25 mg and 0.5 mg administered orally once dai...
    Medical condition: Relapsing-remitting multiple sclerosis.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) BE (Completed) NL (Completed) SK (Completed) GB (Completed) DE (Completed) FR (Completed) FI (Completed) GR (Completed) HU (Completed) IE (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2011-004651-40 Sponsor Protocol Number: SNOXA12C301 Start Date*: 2012-03-05
    Sponsor Name:NOXXON Pharma AG
    Full Title: A multi-center, open label, uncontrolled, Phase IIa clinical trial evaluating the safety and efficacy of NOX-A12 in combination with a background therapy of bortezomib and dexamethasone (VD) in pre...
    Medical condition: Relapsed multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004087-31 Sponsor Protocol Number: CLBH589B2203 Start Date*: 2007-02-22
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase II Study Of Oral LBH589 In Adult Patients With Multiple Myeloma Who Have Received At Least Two Prior Lines Of Therapy And Whose Disease Is Refractory To The Most Recent Line Of Therapy
    Medical condition: Patients with relapsed multiple myeloma who have received at least two prior lines of therapy and whose disease is refractory to the most recent line of therapy. Prior therapy must have included bo...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) IT (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000944-26 Sponsor Protocol Number: HOVON 65 MM / GMMG-HD4 Start Date*: 2007-05-02
    Sponsor Name:HOVON foundation
    Full Title: A randomized phase III study on the effect of Bortezomib combined with Adriamycin, Dexamethasone (AD) for induction treatment, followed by High Dose Melphalan and Bortezomib alone during maintenanc...
    Medical condition: multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10028228 Multiple myeloma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-004954-34 Sponsor Protocol Number: 28981 Start Date*: 2008-12-12
    Sponsor Name:Merck Serono S.A. - Geneva, an affiliate of Merck KGaA, Darmstadt, Germany
    Full Title: Double-blind extension of the study 27025 (REFLEX) to obtain long-term follow-up data in patients with clinically definite MS and patients with a first demyelinating event at high risk of convertin...
    Medical condition: Subjects of high risk of converting to Multiple Sclerosis or subjects already converted to Multiple Sclerosis.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) AT (Completed) FI (Completed) ES (Completed) PT (Completed) EE (Completed) DE (Completed) BE (Completed) LV (Completed) GR (Completed) IT (Completed) FR (Completed) BG (Completed) PL (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2007-001162-32 Sponsor Protocol Number: CAMMS 32400507 Start Date*: 2007-12-24
    Sponsor Name:Genzyme Corporation
    Full Title: A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Patie...
    Medical condition: Relapsing Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) SE (Completed) DE (Completed) FR (Completed) BE (Completed) ES (Completed) CZ (Completed) AT (Completed) IT (Completed) DK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-018893-19 Sponsor Protocol Number: 339 Start Date*: 2011-03-25
    Sponsor Name:Aeterna Zentaris GmbH
    Full Title: A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients Previously Treated with Bortezomib
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) SK (Prematurely Ended) ES (Prematurely Ended) IE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-003707-12 Sponsor Protocol Number: MM-ALLO-06-07 Start Date*: 2007-10-22
    Sponsor Name:FONDAZIONE NEOPLASIE SANGUE ONLUS
    Full Title: Tandem Autografting-Allografting after Induction Chemotherapy with “New Drugs” For Newly Diagnosed Myeloma
    Medical condition: Newly Diagnosed Myeloma patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028228 Multiple myeloma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 27 19:31:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA